Popularity #2,966Earnings are out
BlossomHill Therapeutics (BLSM)
Develops oral small-molecule cancer therapies for EGFR, CLK and KRAS targets.
$22.85
vs last close−2.40 (−9.52%)
No ownership filings on record for this listing.
Develops oral small-molecule cancer therapies for EGFR, CLK and KRAS targets.
No ownership filings on record for this listing.